Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety extension study of Zorblisa (SD-101-6.0) in epidermolysis bullosa
2014-005679-96Phase 3Terminated
- Sponsor
- Scioderm
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of allantoin in epidermolysis bullosa (EB), epidermolysis bullosa simplex (EBS), Recessive Dystrophic Epidermolysis Bullosa (RDEB), sponsored by Scioderm. Started Feb 2015; status: terminated.
02
Drugs
allantoin
03
Conditions
epidermolysis bullosa (EB)epidermolysis bullosa simplex (EBS)Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Beyond the preview
Go deeper on 2014-005679-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005679-96.